Transplant characteristics
| Characteristic . | N (%) . |
|---|---|
| Donor type, no. (%) | 170 |
| Syngeneic | 3 (2) |
| Allogeneic | 167 (92) |
| Related donor | 83 (50) |
| HLA-matched | 79 (95) |
| HLA-mismatched | 4 (5) |
| Unrelated donor | 84 (50) |
| HLA-matched | 66 (79) |
| HLA-mismatched | 18 (21) |
| Conditioning for allogeneic HCT, no. (%) | 167 |
| Bu* 16 mg/kg oral + Cy 120 mg/kg | 91 (54) |
| Bu* 16 mg/kg oral + Cy 120 mg/kg + ATG | 15 (9) |
| Cy 120 mg/kg + Bu* 16 mg/kg IV | 18 (11) |
| Flu 120 mg/m2 + Bu* 16 mg/kg oral | 3 (2) |
| Flu 250 mg/m2 + Bu* 16 mg/kg IV + ATG | 4 (2) |
| Flu 120 mg/m2 + Bu* 12.8 mg/kg IV + ATG | 3 (2) |
| Bu* 16 mg/kg oral + TBI 2 Gy | 1 |
| Bu 7 mg/kg oral + TBI 12 Gy | 8 (5) |
| Cy 120 mg/kg + TBI 12-14 Gy | 5 (3) |
| Flu 150 mg/m2 + melphalan 140 mg/kg | 3 (2) |
| Treosulfan 42 g/m2 + Flu 150 mg/m2 | 1 |
| Flu 90 mg/m2 + TBI 2-3 Gy | 13 (8) |
| I-131 + Flu 90 mg/m2 + TBI 2 Gy | 1 |
| Cy 29 mg/kg + Flu 120 mg/m2 + TBI 2 Gy + Cy 50 mg/kg† | 1 |
| Source of stem cells, no. (%) | 170 |
| Bone marrow | 45 (26) |
| Peripheral blood | 125 (74) |
| GVHD prophylaxis for allogeneic HCT, no. (%) | 167 |
| Cyclosporine + methotrexate | 100 (60) |
| Tacrolimus + methotrexate | 49 (29) |
| Cyclosporine + mycophenolate | 14 (9) |
| Tacrolimus + mycophenolate | 4 (2) |
| Characteristic . | N (%) . |
|---|---|
| Donor type, no. (%) | 170 |
| Syngeneic | 3 (2) |
| Allogeneic | 167 (92) |
| Related donor | 83 (50) |
| HLA-matched | 79 (95) |
| HLA-mismatched | 4 (5) |
| Unrelated donor | 84 (50) |
| HLA-matched | 66 (79) |
| HLA-mismatched | 18 (21) |
| Conditioning for allogeneic HCT, no. (%) | 167 |
| Bu* 16 mg/kg oral + Cy 120 mg/kg | 91 (54) |
| Bu* 16 mg/kg oral + Cy 120 mg/kg + ATG | 15 (9) |
| Cy 120 mg/kg + Bu* 16 mg/kg IV | 18 (11) |
| Flu 120 mg/m2 + Bu* 16 mg/kg oral | 3 (2) |
| Flu 250 mg/m2 + Bu* 16 mg/kg IV + ATG | 4 (2) |
| Flu 120 mg/m2 + Bu* 12.8 mg/kg IV + ATG | 3 (2) |
| Bu* 16 mg/kg oral + TBI 2 Gy | 1 |
| Bu 7 mg/kg oral + TBI 12 Gy | 8 (5) |
| Cy 120 mg/kg + TBI 12-14 Gy | 5 (3) |
| Flu 150 mg/m2 + melphalan 140 mg/kg | 3 (2) |
| Treosulfan 42 g/m2 + Flu 150 mg/m2 | 1 |
| Flu 90 mg/m2 + TBI 2-3 Gy | 13 (8) |
| I-131 + Flu 90 mg/m2 + TBI 2 Gy | 1 |
| Cy 29 mg/kg + Flu 120 mg/m2 + TBI 2 Gy + Cy 50 mg/kg† | 1 |
| Source of stem cells, no. (%) | 170 |
| Bone marrow | 45 (26) |
| Peripheral blood | 125 (74) |
| GVHD prophylaxis for allogeneic HCT, no. (%) | 167 |
| Cyclosporine + methotrexate | 100 (60) |
| Tacrolimus + methotrexate | 49 (29) |
| Cyclosporine + mycophenolate | 14 (9) |
| Tacrolimus + mycophenolate | 4 (2) |